| Matthew S Callander, MD | |
|
1414 W Fair Ave, Suite 36, Marquette, MI 49855-2675 | |
| (906) 225-3864 | |
| (906) 225-3851 |
| Full Name | Matthew S Callander |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 14 Years |
| Location | 1414 W Fair Ave, Marquette, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568773588 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 4301096929 (Michigan) | Secondary |
| 207Q00000X | Family Medicine | 4301096929 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marquette General Hospital | Marquette, MI | Hospital |
| Mercy Medical Center - Cedar Rapids | Cedar rapids, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Apogee Medical Group Michigan Pc | 9931347879 | 35 |
| Cogent Healthcare Of Iowa, Pc | 3779517941 | 52 |
News Archive
Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
Dear Editor: Scientists World-Wide Battle a Narrow View of Alzheimer's Cause, incorrectly implies Alzheimer science is headed down a blind alley. The real issue is inadequate funding.
Two proteins that are implicated in autism have been found to control the strength and balance of nerve-cell connections, researchers at UT Southwestern Medical Center have found.
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of Michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013180181 PECOS PAC ID: 4486703170 Enrollment ID: O20090529000290 |
News Archive
Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
Dear Editor: Scientists World-Wide Battle a Narrow View of Alzheimer's Cause, incorrectly implies Alzheimer science is headed down a blind alley. The real issue is inadequate funding.
Two proteins that are implicated in autism have been found to control the strength and balance of nerve-cell connections, researchers at UT Southwestern Medical Center have found.
› Verified 5 days ago
| Entity Name | Sound Inpatient Physicians-michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639311996 PECOS PAC ID: 5395896849 Enrollment ID: O20090624000252 |
News Archive
Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
Dear Editor: Scientists World-Wide Battle a Narrow View of Alzheimer's Cause, incorrectly implies Alzheimer science is headed down a blind alley. The real issue is inadequate funding.
Two proteins that are implicated in autism have been found to control the strength and balance of nerve-cell connections, researchers at UT Southwestern Medical Center have found.
› Verified 5 days ago
| Entity Name | Dlp Marquette Physician Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487902995 PECOS PAC ID: 9931359601 Enrollment ID: O20121016000312 |
News Archive
Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
Dear Editor: Scientists World-Wide Battle a Narrow View of Alzheimer's Cause, incorrectly implies Alzheimer science is headed down a blind alley. The real issue is inadequate funding.
Two proteins that are implicated in autism have been found to control the strength and balance of nerve-cell connections, researchers at UT Southwestern Medical Center have found.
› Verified 5 days ago
| Entity Name | Apogee Medical Group Michigan Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053655134 PECOS PAC ID: 9931347879 Enrollment ID: O20130604000688 |
News Archive
Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
Dear Editor: Scientists World-Wide Battle a Narrow View of Alzheimer's Cause, incorrectly implies Alzheimer science is headed down a blind alley. The real issue is inadequate funding.
Two proteins that are implicated in autism have been found to control the strength and balance of nerve-cell connections, researchers at UT Southwestern Medical Center have found.
› Verified 5 days ago
| Entity Name | Adfinitas Health At Up Marquette, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205336260 PECOS PAC ID: 7315201480 Enrollment ID: O20180426001547 |
News Archive
Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
Dear Editor: Scientists World-Wide Battle a Narrow View of Alzheimer's Cause, incorrectly implies Alzheimer science is headed down a blind alley. The real issue is inadequate funding.
Two proteins that are implicated in autism have been found to control the strength and balance of nerve-cell connections, researchers at UT Southwestern Medical Center have found.
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of Michigan -tcg, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639658172 PECOS PAC ID: 3870920176 Enrollment ID: O20200226002368 |
News Archive
Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
Dear Editor: Scientists World-Wide Battle a Narrow View of Alzheimer's Cause, incorrectly implies Alzheimer science is headed down a blind alley. The real issue is inadequate funding.
Two proteins that are implicated in autism have been found to control the strength and balance of nerve-cell connections, researchers at UT Southwestern Medical Center have found.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew S Callander, MD 1414 W Fair Ave, Suite 36, Marquette, MI 49855-2675 Ph: (906) 225-3864 | Matthew S Callander, MD 1414 W Fair Ave, Suite 36, Marquette, MI 49855-2675 Ph: (906) 225-3864 |
News Archive
Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.
BioTrends is pleased to announce the publication of the second wave of a syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis (RA). This report is the second in a three-wave series derived from on-line survey responses from 80 rheumatologists and qualitative interviews with 20 rheumatologists.
Dear Editor: Scientists World-Wide Battle a Narrow View of Alzheimer's Cause, incorrectly implies Alzheimer science is headed down a blind alley. The real issue is inadequate funding.
Two proteins that are implicated in autism have been found to control the strength and balance of nerve-cell connections, researchers at UT Southwestern Medical Center have found.
› Verified 5 days ago
Spring L Madosh, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 107 W Main St, Marquette, MI 49855 Phone: 906-225-3988 Fax: 906-225-4707 | |
Lyle J Vanderschaaf, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 420 W Magnetic St, Suite Er, Marquette, MI 49855 Phone: 888-674-0854 Fax: 906-225-3370 | |
Kathryn Lerche, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1414 W Fair Ave, Suite 36, Marquette, MI 49855 Phone: 906-225-3864 | |
Thomas Kates, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1414 W Fair Ave Ste 249, Marquette, MI 49855 Phone: 906-449-2900 Fax: 906-372-3230 | |
Dr. Cynthia K Lack, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 425 Fisher St, Marquette, MI 49855 Phone: 906-226-4618 Fax: 906-226-5317 | |
Siddhesh Ramesh Lotlikar, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1414 W Fair Avenue, Suite 36, Marquette, MI 49855 Phone: 906-225-3864 Fax: 906-225-3851 | |
Dr. Kayleen P Papin, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 1401 Presque Isle Avenue, Health Center, Marquette, MI 49855 Phone: 906-227-2355 Fax: 906-227-2332 |